Publications by authors named "S Venkatesh Rajkumar"
Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial datasets. There is also limited data on the association between frailty and patient-reported outcomes, and the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in newly diagnosed MM patients.
View Article and Find Full Text PDFCause of death (COD) in POEMS (polyneuropathy, organomegaly, endocrinopathies, monoclonal protein and skin changes) syndrome is not well described. We investigated COD in patients with POEMS syndrome treated at Mayo Clinic between 2000 and 2022. Of the 89 deaths, 49 patients had known COD and were the subject of this study.
View Article and Find Full Text PDFBackground: Non-small cell lung cancer (NSCLC) patients often develop brain metastases (BMs), complicating management. We have shown that increasing frailty is associated with decreased overall survival (OS) and central nervous system progression free survival (PFS) for patients undergoing stereotactic radiosurgery (SRS) to BMs. Leveraging the International Radiosurgery Research Foundation, we sought to expand upon these findings, in NSCLC specifically.
View Article and Find Full Text PDFBackground: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.
Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.
Article Synopsis
- - This study analyzed real-world data on high-risk smoldering multiple myeloma (SMM) patients using the Flatiron Health database to assess their risk of disease progression and death.
- - High-risk patients showed significantly increased probabilities of progressing to active multiple myeloma (MM), dying, or progressing on first-line treatment compared to non-high-risk patients, with risk ratios ranging from 1.7 to 4.0.
- - The findings underline the poorer outcomes for high-risk SMM patients and emphasize the importance of early intervention strategies for better management.